Effect of high-dose milnacipran in patients with depression

Masatoshi Hayashi, Masaru Mimura, Tempei Otsubo, Kunitoshi Kamijima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran > 100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose mitnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.

Original languageEnglish
Pages (from-to)699-702
Number of pages4
JournalNeuropsychiatric Disease and Treatment
Volume3
Issue number5
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Depression
Paroxetine
milnacipran
Antidepressive Agents
Inpatients

Keywords

  • Dual-action antidepressant
  • High-dose
  • Milnacipran
  • Paroxetine
  • Pharmacotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Effect of high-dose milnacipran in patients with depression. / Hayashi, Masatoshi; Mimura, Masaru; Otsubo, Tempei; Kamijima, Kunitoshi.

In: Neuropsychiatric Disease and Treatment, Vol. 3, No. 5, 2007, p. 699-702.

Research output: Contribution to journalArticle

Hayashi, M, Mimura, M, Otsubo, T & Kamijima, K 2007, 'Effect of high-dose milnacipran in patients with depression', Neuropsychiatric Disease and Treatment, vol. 3, no. 5, pp. 699-702.
Hayashi, Masatoshi ; Mimura, Masaru ; Otsubo, Tempei ; Kamijima, Kunitoshi. / Effect of high-dose milnacipran in patients with depression. In: Neuropsychiatric Disease and Treatment. 2007 ; Vol. 3, No. 5. pp. 699-702.
@article{5f603af797f448fd906d9c505c17b06a,
title = "Effect of high-dose milnacipran in patients with depression",
abstract = "To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran > 100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose mitnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.",
keywords = "Dual-action antidepressant, High-dose, Milnacipran, Paroxetine, Pharmacotherapy",
author = "Masatoshi Hayashi and Masaru Mimura and Tempei Otsubo and Kunitoshi Kamijima",
year = "2007",
language = "English",
volume = "3",
pages = "699--702",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Effect of high-dose milnacipran in patients with depression

AU - Hayashi, Masatoshi

AU - Mimura, Masaru

AU - Otsubo, Tempei

AU - Kamijima, Kunitoshi

PY - 2007

Y1 - 2007

N2 - To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran > 100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose mitnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.

AB - To investigate the antidepressant effect of high-dose milnacipran, we retrospectively compared three groups of inpatients with major depression; those who were given milnacipran > 100-150 mg/day (high-dose milnacipran group), those treated with milnacipran at maximum doses of 50-100 mg/day (standard-dose milnacipran group), and those treated with paroxetine at maximum doses of 40 mg/day (paroxetine group). The Hamilton Depression Rating Scale (HAM-D) scores of the three groups showed significant decrease at discharge compared to the scores at admission, indicating improvement of depressive symptoms for each group. However, the mean HAM-D score on admission was significantly lower for the standard-dose milnacipran group than the high-dose mitnacipran and paroxetine groups. Additional intermediate assessment of the high-dose milnacipran group showed that the effect of milnacipran was dose-dependent with an additional improvement when patients were increase from 100 to 150 mg/day. These results suggest that patients suffering from moderate to severe depression with relative high HAM-D scores may benefit from treatment with high-dose milnacipran.

KW - Dual-action antidepressant

KW - High-dose

KW - Milnacipran

KW - Paroxetine

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=36049017053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36049017053&partnerID=8YFLogxK

M3 - Article

C2 - 19300602

AN - SCOPUS:36049017053

VL - 3

SP - 699

EP - 702

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 5

ER -